Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced positive topline data from the open-label Phase 2 clinical trial (ATH434-202) of ATH434 in patients with multiple syst...